Compare Lennar Corporation (LEN) vs Tango Therapeutics Inc. (TNGX) Price & Performance

Lennar (LEN) trades at $73.53, down 1.5% on the day, with a bearish technical signal and recent earnings misses. The homebuilder shows declining revenue and profit margins, with 2025 revenue at $34.19B and net income of $2.08B. Valuation metrics appear attractive with P/E of 14.19 and P/B of 0.83, but cash flow trends show negative net cash flow of -$1.16B in 2025. Berkshire Hathaway has been accumulating shares, building an 11.2% stake as of October 2026.

Lennar presents a value opportunity with below-book valuation and strong institutional interest, but faces headwinds from declining profitability, negative cash flow, and housing market challenges. The stock trades below the $77.38 consensus price target, offering potential upside if operational improvements materialize, though execution risks and macroeconomic pressures remain concerns.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.